UHTR


Thema
abonnieren
Beiträge: 5
Zugriffe: 8.537 / Heute: 1
Utd. Therapeutics. 581,17 $ +0,63% Perf. seit Threadbeginn:   +236,01%
 
Tamakoschy:

UHTR

2
28.03.15 17:48
seekingalpha.com/article/...on-good-news-why-i-bought-that-dip
www.unither.com
Antworten

Werbung

Entdecke die beliebtesten ETFs von Xtrackers

Xtrackers MSCI Korea UCITS ETF 1C
Perf. 12M: +157,21%
Xtrackers MSCI Taiwan UCITS ETF 1D
Perf. 12M: +81,03%
Xtrackers MSCI Taiwan UCITS ETF 1C
Perf. 12M: +80,70%
Xtrackers Nikkei 225 UCITS ETF 2D - EUR Hedged
Perf. 12M: +69,91%
Xtrackers MSCI Brazil UCITS ETF 1C
Perf. 12M: +69,04%

Tamakoschy:

United Therapeutics Corporation

 
29.03.15 21:28
www.unither.com
financials.morningstar.com/ratios/r.html?t=UTHR
markets.ft.com/research/Markets/Tearsheets/Forecasts?…
www.macroaxis.com/invest/compare/UTHR

Kurzporträt



Logo United Therapeutics Corpor
Develops pharmaceutical products

United Therapeutics Corp. operates as a biotechnology company, which focuses on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

The company operates in two business segments: Pharmaceuticals and Telemedicine.

Its primary product Remodulin is used for the treatment of pulmonary arterial hypertension and the company also develops glycol-biological antiviral agents for the treatment of infectious diseases, such as Hepatitis C. United Therapeutics was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

de.4-traders.com/UNITED-THERAPEUTICS-CORPO-11262/fundamentals/
Antworten
Balu4u:

Gewinn im Quartal verdoppelt

 
27.01.20 20:23
www.analystratings.com/articles/...a-buy-rating-from-wedbush/
Antworten
Balu4u:

3tes Buy rating

 
03.02.20 19:51
www.analystratings.com/articles/...ed-its-third-buy-in-a-row/
Antworten
Vassago:

UTHR 228$

 
21.04.23 15:35
  • Dr. Reddy's kündigt die Einführung der Treprostinil Injektion an, einer therapeutischen äquivalenten generischen Version von Remodulin (Treprostinil) Injektion

www.sec.gov/Archives/edgar/data/1135951/...drr0473_ex99-1.htm
Remodulin ist UTHR's zweitstärkstes Produkt, gemessen am Umsatz von 500 Mio. $ in 2022

Antworten
Auf neue Beiträge prüfen
Es gibt keine neuen Beiträge.


Börsen-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem United Therapeutics Forum

Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
2 4 UHTR Tamakoschy Vassago 21.04.23 15:35

--button_text--